Recent evidence indicates that transthyretin (TTR), the major transport protein for thyroxine [1] and retinol binding protein [2] , plays important roles in amyloid-β (Aβ) metabolism. Transthyretin has been demonstrated to bind Aβ in vitro [3, 4] and in vivo [5, 6] , colocalize in Aβ plaques and within neurons containing intracellular Aβ [7] , and recent evidence suggests it might act as a transport protein for Aβ. Additionally, sAβPP-driven expression of transthyretin appears to be necessary for protection against Aβ induced neuronal death [7] . Therefore, the regulation of the expression of TTR may have important consequences for the deposition of Aβ in the brain.
The findings of Tang and colleagues reported in JAD [8] that 17β-estradiol increases the gene expression of TTR in ovariectomized mice implicates reproductive hormones in the regulation of amyloid transport and deposition. While the sex steroids are undoubtedly important for brain function, they are controlled by a complex feedback loop that is made up of numerous other hormones including: gonadotropin releasing hormone (GnRH); the gonadotropins-luteinizing hormone (LH) and follicle stimulating hormone (FSH); inhibins; activins; and follistatin. This therefore adds to the complexity of interpreting these results since the perturbation of serum sex steroids via ovariectomy or sex steroid add-back affects the serum concentrations of all members of the hypothalamic-pituitary-gonadal (HPG) axis [9] . Add-back estrogen after ovariectomy fails to take these other hormones into account and is not synonymous with a physiologically normal HPG axis. Receptors for members of the HPG axis including GnRH, LH and activins are present throughout the body and like estrogen, progesterone and androgen receptors, are particularly localized to the limbic system of the brain. The loss of peripheral sex steroid and inhibin production following menopause and during andropause while leading to decreased signaling via sex steroid receptors also results in marked increases in signaling via GnRH, LH and activin receptors [10] . Given these reciprocal changes in signaling and the fact that GnRH, LH and activins have known functions in the brain, the effects attributed to sex steroids could just as easily be attributed to other hormones of the axis. While the authors mention in their discussion that LH drives AβPP processing towards the amyloidogenic pathway in vitro and in vivo [11] , they overlook the possibility that TTR expression also might be modulated by other members of the HPG axis following ovariectomy.
That hormones may modulate TTR-induced Aβ deposition as a causatory mechanism for the disease needs to be examined in light of the fact that TTR potently regulates mitogensis in neuroblastoma cells, possibly via the binding of thyroid hormones [12] , and that cellcycle re-entry has been implicated as a causative mechanism in the disease [13] . Downregulation of TTR expression would therefore increase mitogenesis, and the generation of Aβ which has been strongly associated with cell cycle re-entry [14, 15] .
These and other recent observations illustrate the need to examine the entire HPG axis when interpreting results obtained from studies involving menopause/andropause, castration, hormone replacement and modulation of receptor expression and/or signaling. One method in addition to surgical castration that might help shed light on this issue is medical castration with GnRH agonists and antagonists. In this case, as opposed to surgically castrated animals which have minimal sex steroids and elevated LH, medically castrated animals will have minimal serum concentrations of sex steroids and suppressed LH. Studies in animals are underway to confirm the role of these hormones in promoting AD neuropathology, and their use in providing an animal model for the disease. Human clinical trials using the GnRH agonist, leuprolide acetate, to suppress LH in patients with AD also are currently underway and should provide further insight into these issues.
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